BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas

American Journal of Surgical Pathology

Volumn 37, Issue 1, 2013, Pages 138-146

  Garg, Karuna ^a   Levine, Douglas A ^a   Olvera, Narciso ^a   Dao, Fanny ^a   Bisogna, Maria ^a   Secord, Angeles Alvarez ^b   Berchuck, Andrew ^b   Cerami, Ethan ^a   Schultz, Nikolaus ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

BRCA1; BRCA1 immunohistochemistry; ovarian carcinoma; protein expression; serous carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; COHORT ANALYSIS; CYSTADENOCARCINOMA; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MUTATION; OBSERVER VARIATION; OVARY TUMOR; PATHOLOGY; REPRODUCIBILITY;

BRCA1 PROTEIN; BRCA2 PROTEIN; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871620943     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31826cabbd     Document Type: Article

References (22)

1. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351: 2519-2529.
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
3. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28:3555-3561.
4. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
5. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570-3576.
6. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261-268.
7. Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochem-istry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33:925-933.
8. Modica I, Soslow RA, Black D, et al. Utility of immunohistochem-istry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol. 2007;31:744-751.
9. Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29:2247-2252.
10. Resnick K, Straughn JM Jr, Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol. 2009;114:530-536.
11. King TA, Li W, Brogi E, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol. 2007;14:2510-2518.
12. Kashima K, Oite T, Aoki Y, et al. Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res. 2000;91:399-409.
13. Byrne TJ, Reece MT, Adams LA, et al. An antibody assay predictive of BRCA1 mutations in ovarian tumors and normal tissue. Oncol Rep. 2000;7:949-953.
14. Carser JE, Quinn JE, Michie CO, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol. 2011;123: 492-498.
15. Radosa MP, Hafner N, Camara O, et al. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer. 2011;21:1399-1406.
16. Weberpals JI, Tu D, Squire JA, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol. 2011;22:2403-2410.
17. Skytte AB, Waldstrøm M, Rasmussen AA, et al. Identification of BRCA1-deficient ovarian cancers. Acta Obstet Gynecol Scand. 2011;90:593-599.
18. Vaz FH, Machado PM, Brandao RD, et al. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohisto-chemistry as an additional method in the selection of patients. J Histochem Cytochem. 2007;55:1105-1113.
19. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625-636.
20. Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103:334-346.
21. Dedes KJ, Wilkerson PM, Wetterskog D, et al. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192-1199.
22. Ibragimova I, Cairns P. Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. Methods Mol Biol. 2011;780:277-291.